SITUATION WITH PREPARATIONS OF BLOOD AT THE MARKETOF UKRAINE

Melnichuk E. R., Begunova N.V., Strelnikov L.S., Strilets O.P. The National University of Pharmacy, Kharkiv, Ukraine Jekan454647@ukr.net

Preparations of blood are the remedies got from blood. There are preparations of complex, immunological, hemostatic, antianaemic and stimulant action.

Until recently, the production of blood products and their quality remained virtually unchanged both in Ukraine and the former Soviet Union. The function of harvesting and processing of blood in the country was given to the numerically small network of centers and blood transfusion stations, and a few plants for processing plasma. All of them were owned by the state. Equipment and testing standards are not kept even the most basic requirements for the safety of donated blood and blood components. There was a need to reorganize blood services in the country and, above all, the introduction of strict requirements of quality assurance harvested blood.

In developed countries, manufacturers use modern tests for the analysis of raw materials. The test is based on the polymerase chain reaction is used along with the known enzyme immunoassay, feels much more-flax. It is obligatory to use specific procedures to inactivate viruses. The manufacturer must prove (validate) the effectiveness and completeness of the inactivation of the pathogen in the production process.

Today in Ukraine manufacturers of blood products are private enterprises "Pharmstandard - Biolik" and "Biopharma". Thanks to foreign investment they reconstructed and launched production of products conforming to international standards. However, in production, they fully use the plasma from the European Union, in particular from Slovakia. These raw materials meet the requirements of the European Pharmacopoeia, passed the registration on the territory of Ukraine.

Only "Biopharma" is a producer of blood products in the territory of the former Soviet Union and Eastern Europe, where the production of immunoglobulin implemented global standards viral safety of blood products.

Ukraine has also recorded blood products of foreign production, for example, drugs Swiss pharmaceutical company "Genfa Medica SA", Belarusian-Dutch joint venture "Farmland".

Several years ago, Ukraine has a policy of import substitution of high-tech foreign lifesaving drugs. Experience and practice show that the cost of medicines domestic production is several times lower than foreign counterparts - it allows receiving quality care to more patients.